HIGHLIGHTS
- who: Coates and colleagues from the Eli Lilly and Company, India have published the article: Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results Author, in the Journal: (JOURNAL)
- how: Structural progression data were analyzed using linear extrapolation.
SUMMARY
Objectives To evaluate the three-year efficacy and safety of ixekizumab with and without concomitant conventional synthetic disease-modifying antirheumatic drug (csDMARD) use in patients with active psoriatic arthritis (PsA). Method Patients with . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.